Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis

Jens H Henriksen; Flemming Bendtsen; Erik Feldager Hansen; Søren Møller

Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis

Jens H Henriksen, Flemming Bendtsen, Erik Feldager Hansen, Søren Møller

Institut for Klinisk Medicin

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

96 Citationer (Scopus)

Abstract

Udgivelsesdato: 2004-Feb

Originalsprog	Engelsk
Tidsskrift	Journal of Hepatology
Vol/bind	40
Udgave nummer	2
Sider (fra-til)	239-46
Antal sider	7
ISSN	0168-8278
Status	Udgivet - 2004

Bibliografisk note

Keywords: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Cardiac Output; Female; Heart Rate; Humans; Liver Cirrhosis, Alcoholic; Long QT Syndrome; Male; Middle Aged; Propranolol; Vascular Resistance

Citationsformater

@article{dedc6bb01bcc11df8ed1000ea68e967b,

title = "Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis",

abstract = "BACKGROUND/AIMS: Earlier studies have shown a prolonged frequency-adjusted Q-T interval (QTc>0.440 s(1/2)) in a substantial fraction of patients with cirrhosis. The effect of beta-blockade on QTc is unknown, and its determination was the aim of the study. METHODS: Seventeen patients with cirrhosis received 80 mg propranolol orally during a haemodynamic investigation with measurements at baseline and 90 min after propranolol ingestion. RESULTS: Beta-blockade reduced cardiac output (-21%, P<0.001), heart rate (-20%, P<0.001), and the hepatic venous pressure gradient (HVPG, -17%, P<0.02). The mean QTc=0.460 s(1/2) was prolonged compared to 0.410 s(1/2) in age-matched controls (P<0.01). Whereas QTc decreased during beta-blockade in the cirrhotic patients (from 0.460 to 0.440 s(1/2), P<0.01), no effect was found in the subgroup with normal QTc (0.429 vs. 0.422 s(1/2), ns), and a reduction was seen in the patients with prolonged QTc (from 0.488 to 0.456 s(1/2), P<0.01). The percentage decrease in QTc was related to the reduction in HVPG (r=0.48, P=0.03) and cardiac output (r=0.56, P=0.02). CONCLUSIONS: Acute non-selective beta-blockade reduces prolonged QTc towards normal values in patients with cirrhosis. The clinical significance of QTc reduction in arrhythmia is a topic for future research.",

author = "Henriksen, {Jens H} and Flemming Bendtsen and Hansen, {Erik Feldager} and S{\o}ren M{\o}ller",

note = "Keywords: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Cardiac Output; Female; Heart Rate; Humans; Liver Cirrhosis, Alcoholic; Long QT Syndrome; Male; Middle Aged; Propranolol; Vascular Resistance",

year = "2004",

language = "English",

volume = "40",

pages = "239--46",

journal = "Journal of Hepatology, Supplement",

issn = "0169-5185",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis

AU - Henriksen, Jens H

AU - Bendtsen, Flemming

AU - Hansen, Erik Feldager

AU - Møller, Søren

N1 - Keywords: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Cardiac Output; Female; Heart Rate; Humans; Liver Cirrhosis, Alcoholic; Long QT Syndrome; Male; Middle Aged; Propranolol; Vascular Resistance

PY - 2004

Y1 - 2004

N2 - BACKGROUND/AIMS: Earlier studies have shown a prolonged frequency-adjusted Q-T interval (QTc>0.440 s(1/2)) in a substantial fraction of patients with cirrhosis. The effect of beta-blockade on QTc is unknown, and its determination was the aim of the study. METHODS: Seventeen patients with cirrhosis received 80 mg propranolol orally during a haemodynamic investigation with measurements at baseline and 90 min after propranolol ingestion. RESULTS: Beta-blockade reduced cardiac output (-21%, P<0.001), heart rate (-20%, P<0.001), and the hepatic venous pressure gradient (HVPG, -17%, P<0.02). The mean QTc=0.460 s(1/2) was prolonged compared to 0.410 s(1/2) in age-matched controls (P<0.01). Whereas QTc decreased during beta-blockade in the cirrhotic patients (from 0.460 to 0.440 s(1/2), P<0.01), no effect was found in the subgroup with normal QTc (0.429 vs. 0.422 s(1/2), ns), and a reduction was seen in the patients with prolonged QTc (from 0.488 to 0.456 s(1/2), P<0.01). The percentage decrease in QTc was related to the reduction in HVPG (r=0.48, P=0.03) and cardiac output (r=0.56, P=0.02). CONCLUSIONS: Acute non-selective beta-blockade reduces prolonged QTc towards normal values in patients with cirrhosis. The clinical significance of QTc reduction in arrhythmia is a topic for future research.

AB - BACKGROUND/AIMS: Earlier studies have shown a prolonged frequency-adjusted Q-T interval (QTc>0.440 s(1/2)) in a substantial fraction of patients with cirrhosis. The effect of beta-blockade on QTc is unknown, and its determination was the aim of the study. METHODS: Seventeen patients with cirrhosis received 80 mg propranolol orally during a haemodynamic investigation with measurements at baseline and 90 min after propranolol ingestion. RESULTS: Beta-blockade reduced cardiac output (-21%, P<0.001), heart rate (-20%, P<0.001), and the hepatic venous pressure gradient (HVPG, -17%, P<0.02). The mean QTc=0.460 s(1/2) was prolonged compared to 0.410 s(1/2) in age-matched controls (P<0.01). Whereas QTc decreased during beta-blockade in the cirrhotic patients (from 0.460 to 0.440 s(1/2), P<0.01), no effect was found in the subgroup with normal QTc (0.429 vs. 0.422 s(1/2), ns), and a reduction was seen in the patients with prolonged QTc (from 0.488 to 0.456 s(1/2), P<0.01). The percentage decrease in QTc was related to the reduction in HVPG (r=0.48, P=0.03) and cardiac output (r=0.56, P=0.02). CONCLUSIONS: Acute non-selective beta-blockade reduces prolonged QTc towards normal values in patients with cirrhosis. The clinical significance of QTc reduction in arrhythmia is a topic for future research.

M3 - Journal article

C2 - 14739094

VL - 40

SP - 239

EP - 246

JO - Journal of Hepatology, Supplement

JF - Journal of Hepatology, Supplement

SN - 0169-5185

IS - 2

ER -